Literature DB >> 23053599

RET promoter variations in familial African degenerative leiomyopathy (ADL): first report of a possible genetic-environmental interaction.

C Van Rensburg1, S W Moore, M Zaahl.   

Abstract

African degenerative leiomyopathy (ADL, DL, Bantu pseudo-Hirschsprung's disease) is a distinctive visceral myopathy, of unknown etiology, occurring in Africa. It has a classical clinical and histologic picture in young indigenous African children. It presents as intestinal pseudo-obstruction with a massive megacolon due to degeneration of smooth muscle without aganglionosis. Because of its late presentation and geographical and ethnic distribution, it is thought to be an acquired degenerative hollow visceral myopathy. Only one previous report of familial recurrence exists. The main Hirschsprung susceptibility gene RET is a potential candidate gene in this condition, because of its role in the development of the intrinsic innervation and ganglia of the smooth muscle layers of the gastro-intestinal tract. We report a second case of familial ADL recurrence and explore possible etiologic causes including variations of the RET gene. Multiple variations in the RET promoter were identified in this case which leads to the possibility of a genetic-environmental predisposition for this condition. We therefore hypothesize that RET may play a modulating role in ADL susceptibility (and possibly other visceral myopathies). It is possible that subtle malformations in the ENS may result from RET dysfunction which then predisposes the individual to environmental influences which initiate the later onset of muscle degeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053599     DOI: 10.1007/s00383-012-3185-4

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  12 in total

1.  Unusual variations of gastrointestinal smooth muscle abnormalities associated with chronic intestinal pseudo-obstruction.

Authors:  S W Moore; J W Schneider; R O C Kaschula
Journal:  Pediatr Surg Int       Date:  2002-01       Impact factor: 1.827

2.  The role of RET genomic variants in infantile hypertrophic pyloric stenosis.

Authors:  A Serra; K Schuchardt; J Genuneit; C Leriche; H S Görgens; H-K Schackert; G Fitze
Journal:  Eur J Pediatr Surg       Date:  2011-12-14       Impact factor: 2.191

Review 3.  Variant Hirschsprung's disease.

Authors:  Prem Puri; Udo Rolle
Journal:  Semin Pediatr Surg       Date:  2004-11       Impact factor: 2.754

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

Review 5.  Idiopathic inflammatory myopathies.

Authors:  Melinda Vincze; Katalin Danko
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-02       Impact factor: 4.098

6.  Degenerative leiomyopathy with massive megacolon. Myopathic form of chronic idiopathic intestinal pseudo-obstruction occurring in indigenous Africans.

Authors:  R O Kaschula; S Cywes; A Katz; J H Louw
Journal:  Perspect Pediatr Pathol       Date:  1987

7.  Non-familial visceral myopathy: clinical and pathologic features of degenerative leiomyopathy.

Authors:  S W Moore; J W Schneider; R D C Kaschula
Journal:  Pediatr Surg Int       Date:  2002-01       Impact factor: 1.827

Review 8.  Degenerative leiomyopathy in African children: a review of current perspectives.

Authors:  R O Kaschula; S W Moore; H Rode; S Cywes
Journal:  East Afr Med J       Date:  1993-04

9.  Hollow visceral myopathy in black South Africans. A report of 14 cases.

Authors:  C Isaacson; H C Wainwright; D G Hamilton; L Ou Tim
Journal:  S Afr Med J       Date:  1985-06-22

Review 10.  Chronic intestinal pseudo-obstruction syndrome in pediatrics. Results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition.

Authors:  J H Vargas; P Sachs; M E Ament
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988 May-Jun       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.